Back

Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Chronic heart failure - Prognosis and prediction of outcome Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Carly Adamson

Forth Valley Royal Hospital, Larbert (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
National Early Warning Score 2 provides independent prognostic information in patients hospitalized with heart failure with preserved ejection fraction
Doctor K. Berge (Nordbyhagen, NO)
Abstract Slides
Presentation thumbnail
Introduction of a new scoring tool to identify clinically stable heart failure patients
Mr A. Gingele (Maastricht, NL)
Abstract Slides
Presentation thumbnail
Prognostic value of liver damage assessed by direct bilirubin and skeletal muscle weakness in patients with heart failure
Mr T. Noda (Suita, JP)
Abstract Slides
Presentation thumbnail
A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)
Doctor K. McDowell (Glasgow, GB)
Abstract Slides
Presentation thumbnail
MR-proADM is a strong independent predictor of long-term all-cause mortality risk in patients with chronic heart failure: results from the E-INH study
Doctor F. Kerwagen (Wuerzburg, DE)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - Prognosis and prediction of outcome

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources